Guggenheim initiated coverage of Pharvaris (PHVS) with a Buy rating and $32 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris Announces 2025 Annual Shareholders Meeting Amidst Phase 3 Trials
- Pharvaris’s Deucrictibant: Expanding Market Reach in Bradykinin-Mediated Angioedemas with Promising Phase 3 Trials
- Pharvaris’s Strategic Advancements and Clinical Progress Justify Buy Rating
- Pharvaris presents data supporting ongoing clinical development of deucrictibant
- Pharvaris: Strong Buy Rating Backed by Clinical Progress and Financial Stability